[go: up one dir, main page]

WO2009033819A3 - Utilisation d'un peptide en tant qu'agent thérapeutique - Google Patents

Utilisation d'un peptide en tant qu'agent thérapeutique Download PDF

Info

Publication number
WO2009033819A3
WO2009033819A3 PCT/EP2008/008187 EP2008008187W WO2009033819A3 WO 2009033819 A3 WO2009033819 A3 WO 2009033819A3 EP 2008008187 W EP2008008187 W EP 2008008187W WO 2009033819 A3 WO2009033819 A3 WO 2009033819A3
Authority
WO
WIPO (PCT)
Prior art keywords
ser
asp
pro
combination
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP2008/008187
Other languages
English (en)
Other versions
WO2009033819A2 (fr
Inventor
Dorian Bevec
Fabio Cavalli
Vera Cavalli
Gerald Bacher
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mondobiotech Laboratories AG
Original Assignee
Mondobiotech Laboratories AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Mondobiotech Laboratories AG filed Critical Mondobiotech Laboratories AG
Publication of WO2009033819A2 publication Critical patent/WO2009033819A2/fr
Publication of WO2009033819A3 publication Critical patent/WO2009033819A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Psychiatry (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention concerne l'utilisation de la combinaison des composés peptidiques Lys-Phe-Arg- Arg-Ser-Leu-Gln-Asp-Thr-Glu-Glu-Lys-Ser-Arg-Ser-Phe-Ser-Ala-Ser- Gln-Ala-Asp-Pro-Leu-Ser-Asp-Pro-Asp-Gln-Met-Asn-Glu-Asp-OH et Gln-Arg-Pro- Arg-Leu-Ser-His-Lys-Gly-Pro-Met-Pro-Phe-OH en tant que composés polythérapeutiques destinés à la prophylaxie et/ou au traitement du cancer, d'une maladie cardiaque et vasculaire, d'une maladie infectieuse, d'une maladie fibreuse, d'une maladie inflammatoire, d'une maladie neurodégénérative ou d'une maladie auto-immune.
PCT/EP2008/008187 2007-09-11 2008-09-09 Utilisation d'un peptide en tant qu'agent thérapeutique Ceased WO2009033819A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP07017749 2007-09-11
EP07017766.2 2007-09-11
EP07017749.8 2007-09-11
EP07017766 2007-09-11

Publications (2)

Publication Number Publication Date
WO2009033819A2 WO2009033819A2 (fr) 2009-03-19
WO2009033819A3 true WO2009033819A3 (fr) 2009-11-05

Family

ID=40452600

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP2008/008187 Ceased WO2009033819A2 (fr) 2007-09-11 2008-09-09 Utilisation d'un peptide en tant qu'agent thérapeutique

Country Status (1)

Country Link
WO (1) WO2009033819A2 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673848B2 (en) 2012-01-27 2014-03-18 Novartis Ag Synthetic apelin mimetics for the treatment of heart failure
WO2013079487A1 (fr) * 2011-11-28 2013-06-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Composition pharmaceutique destinée à une utilisation dans le traitement d'un dysfonctionnement associé au vieillissement
US8921307B2 (en) 2012-11-20 2014-12-30 Novartis Ag Synthetic linear apelin mimetics for the treatment of heart failure
UY35144A (es) 2012-11-20 2014-06-30 Novartis Ag Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca
US9266925B2 (en) 2013-07-25 2016-02-23 Novartis Ag Cyclic polypeptides for the treatment of heart failure
BR112016001376A2 (pt) 2013-07-25 2017-10-24 Novartis Ag bioconjugados de polipeptídeos de apelin sintéticos
CN104436158A (zh) * 2013-09-22 2015-03-25 华中科技大学 Apelin-13在治疗糖尿病肾病中的应用
CN114099637A (zh) * 2021-12-15 2022-03-01 广东省职业病防治院(广东省职业卫生检测中心) Apelin在制备治疗矽肺的药物中的应用

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405608A (en) * 1980-08-28 1983-09-20 Novo Industri A/S Novel peptide
EP1116727A1 (fr) * 1998-09-25 2001-07-18 Takeda Chemical Industries, Ltd. Derive de peptide
WO2004081198A2 (fr) * 2003-03-12 2004-09-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Procedes de modulation de l'angiogenese avec de compositions d'apeline
US20050070459A1 (en) * 2001-11-26 2005-03-31 Brigham And Women"S Hospital Methods for treating autoimmune disorders, and reagents related thereto
US20060045880A1 (en) * 2004-08-23 2006-03-02 Krieg Paul A Methods for modulating angiogenesis and apoptosis with apelin compositions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4405608A (en) * 1980-08-28 1983-09-20 Novo Industri A/S Novel peptide
EP1116727A1 (fr) * 1998-09-25 2001-07-18 Takeda Chemical Industries, Ltd. Derive de peptide
US20050070459A1 (en) * 2001-11-26 2005-03-31 Brigham And Women"S Hospital Methods for treating autoimmune disorders, and reagents related thereto
WO2004081198A2 (fr) * 2003-03-12 2004-09-23 Arizona Board Of Regents On Behalf Of The University Of Arizona Procedes de modulation de l'angiogenese avec de compositions d'apeline
US20060045880A1 (en) * 2004-08-23 2006-03-02 Krieg Paul A Methods for modulating angiogenesis and apoptosis with apelin compositions

Non-Patent Citations (12)

* Cited by examiner, † Cited by third party
Title
HAN ET AL: "Increased colonic apelin production in rodents with experimental colitis and in humans with IBD", REGULATORY PEPTIDES, ELSEVIER SCIENCE BV, NL, vol. 142, no. 3, 14 June 2007 (2007-06-14), pages 131 - 137, XP022116452, ISSN: 0167-0115 *
HOLST J J: "Enteroglucagon.", ANNUAL REVIEW OF PHYSIOLOGY 1997, vol. 59, 1997, pages 257 - 271, XP002540448, ISSN: 0066-4278 *
HUI XIE ET AL: "Apelin suppresses apoptosis of human osteoblasts", APOPTOSIS ; AN INTERNATIONAL JOURNAL ON PROGRAMMED CELL DEATH, KLUWER ACADEMIC PUBLISHERS, BO, vol. 12, no. 1, 21 November 2006 (2006-11-21), pages 247 - 254, XP019463727, ISSN: 1573-675X *
KASAI A ET AL: "Apelin is a novel angiogenic factor in retinal endothelial cells", BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, ACADEMIC PRESS INC. ORLANDO, FL, US, vol. 325, no. 2, 10 December 2004 (2004-12-10), pages 395 - 400, XP004626806, ISSN: 0006-291X *
KLEINZ M J ET AL: "Emerging roles of apelin in biology and medicine", PHARMACOLOGY AND THERAPEUTICS, ELSEVIER, GB, vol. 107, no. 2, 1 August 2005 (2005-08-01), pages 198 - 211, XP004963619, ISSN: 0163-7258 *
LADEIRAS-LOPES RICARDO ET AL: "The apelinergic system: the role played in human physiology and pathology and potential therapeutic applications.", ARQUIVOS BRASILEIROS DE CARDIOLOGIA MAY 2008, vol. 90, no. 5, May 2008 (2008-05-01), pages 343 - 349, XP002539444, ISSN: 1678-4170 *
LEE D K ET AL: "Unravelling the roles of the apelin system: prospective therapeutic applications in heart failure and obesity", TRENDS IN PHARMACOLOGICAL SCIENCES, ELSEVIER, HAYWARTH, GB, vol. 27, no. 4, 1 April 2006 (2006-04-01), pages 190 - 194, XP025029550, ISSN: 0165-6147, [retrieved on 20060401] *
MASRI B ET AL: "Apelin signalling: a promising pathway from cloning to pharmacology", CELLULAR SIGNALLING, ELSEVIER SCIENCE LTD, GB, vol. 17, no. 4, 1 April 2005 (2005-04-01), pages 415 - 426, XP025337469, ISSN: 0898-6568, [retrieved on 20050401] *
OHNEDA A ET AL: "EFFECT OF GLICENTIN-RELATED PEPTIDES UPON THE SECRETION OF INSULIN AND GLUCAGON IN THE CANINE PANCREAS", TOHOKU JOURNAL OF EXPERIMENTAL MEDICINE, vol. 155, no. 2, 1988, pages 197 - 204, XP002540447, ISSN: 0040-8727 *
SAINT-GENIEZ M ET AL: "Expression of the murine msr/apj receptor and its ligand apelin is upregulated during formation of the retinal vessels", MECHANISMS OF DEVELOPMENT, ELSEVIER SCIENCE IRELAND LTD, IE, vol. 110, 1 January 2002 (2002-01-01), pages 183 - 186, XP002992963, ISSN: 0925-4773 *
SORLI S C ET AL: "Therapeutic potential of interfering with apelin signalling", DRUG DISCOVERY TODAY, ELSEVIER, RAHWAY, NJ, US, vol. 11, no. 23-24, 1 December 2006 (2006-12-01), pages 1100 - 1106, XP025027123, ISSN: 1359-6446, [retrieved on 20061201] *
TANG ET AL: "Apelin stimulates proliferation and suppresses apoptosis of mouse osteoblastic cell line MC3T3-E1 via JNK and PI3-K/Akt signaling pathways", PEPTIDES, ELSEVIER, AMSTERDAM, vol. 28, no. 3, 7 February 2007 (2007-02-07), pages 708 - 718, XP005877280, ISSN: 0196-9781 *

Also Published As

Publication number Publication date
WO2009033819A2 (fr) 2009-03-19

Similar Documents

Publication Publication Date Title
WO2009033821A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033797A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009043518A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033819A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
LTC2435432I2 (lt) Apoptozę sukeliantys agentai, skirti vėžio ir imuninių ir autoimuninių ligų gydymui
IL247183A0 (en) Secretory-apoptosis factors for the treatment of cancer and immune and autoimmune diseases
MY161340A (en) Apoptosis-Inducing Agents For The Treatment Of Cancer And Immune And Autoimmune Diseases
PL1951273T3 (pl) Zastosowanie lactobacillus do leczenia chorób autoimmunologicznych
WO2009089635A9 (fr) Traitement de maladies neurodégénératives avec de la progranuline (pgrn)
WO2006058868A3 (fr) Pteridines substituees destinees au traitement de maladies inflammatoires
WO2007135026A3 (fr) Ptéridines substituées
WO2012061390A3 (fr) Compositions et procédés thérapeutiques
WO2012101156A3 (fr) Nouveaux peptides synthétiques et leur utilisation
UA85471C2 (ru) Применение оксикодона для лечения висцеральной боли
WO2009033813A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009043525A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033820A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009046875A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033814A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033818A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009033816A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009046872A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2008009426A9 (fr) Dérivés de 5-cyano-prostacycline utilisés comme agents dans le traitement de maladies auto-immunes
WO2009033809A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique
WO2009043519A3 (fr) Utilisation d'un peptide en tant qu'agent thérapeutique

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08830656

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08830656

Country of ref document: EP

Kind code of ref document: A2